Breyanzi Company is Bristol Myers Squibb (abbreviated as BMY)
Breyanzi Company is Bristol Myers Squibb (abbreviated as BMY)
Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy developed by the American pharmaceutical company Bristol Myers Squibb (BMS) for the first-line treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after treatment. This therapy targets CD19, an antigen highly expressed in B-cell lineage lymphomas, providing selectivity and reducing off-target toxicity.
Introduction to Bristol Myers Squibb
Bristol Myers Squibb was formed by the merger of the former Squibb Laboratories and the former Clinton Pharmaceutical Company, with a history spanning over a century.
Brand Culture
Corporate Vision, Mission, and Values
Bristol Myers Squibb’s corporate vision is “to lead science, change patients’ lives,” and the company works together tirelessly for the future. Adhering to the principle of “patient-centricity,” Bristol Myers Squibb upholds six core values: “integrity, passion, innovation, accountability, urgency, and inclusion.”
Brand Logo
In 2020, Bristol Myers Squibb unveiled a new corporate brand, and at the 4th China International Import Expo in 2021, the company introduced its brand theme – “Hands” protecting life.
Bristol Myers Squibb English and Chinese logos
Bristol Myers Squibb’s new corporate brand The inspiration for the new corporate brand came from patients and employees. As the company’s brand symbol, the “hand” represents healing, giving, and receiving care, while the purple color highlights passion, boldness, and focus. In Bristol Myers Squibb’s view, everyone has someone they want to protect in their life – family members protecting loved ones, parents protecting children, doctors protecting patients, teachers protecting students… And everything Bristol Myers Squibb does is to wholeheartedly and diligently “protect” every life through “science and innovation.”
Development History
Bristol Myers Squibb was formed by the merger of the former Squibb Laboratories, founded in 1858, and the former Clinton Pharmaceutical Company, established in 1887, with a history of over a century in the United States. In 1989, Squibb merged with Bristol-Myers to become a leader in the global healthcare industry. The merged Bristol Myers Squibb became the second-largest pharmaceutical company at the time.
In 2007, Bristol Myers Squibb transformed from a traditional pharmaceutical company to a next-generation biopharmaceutical company, gradually divesting its consumer health, chronic disease, and other businesses to focus more on urgent patient needs in oncology, hematology, and immunology.
In 2019, Bristol Myers Squibb acquired Celgene for $74 billion; in 2020, it acquired MyoKardia for $13.1 billion. With these two major acquisitions as new milestones, Bristol Myers Squibb significantly expanded its product portfolio, forming multiple disease area product lines in hematology, immunology, oncology, cardiovascular disease, and neurological diseases.
In 2021, the anti-PD-1 antibody Opdivo produced by Bristol Myers Squibb was approved for marketing in China. Data from the Pharmakers database shows that in 2020, global sales of this product were approximately $1.682 billion.
On December 26, 2023, Bristol Myers Squibb stated that it would acquire RayzeBio for approximately $4.1 billion to strengthen its cancer drug business.
On May 30, 2024, local time, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for its CAR-T therapy Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior systemic therapies, including those who have received prior Bruton’s tyrosine kinase (BTK) inhibitor therapy.
On June 13, 2024, local time, Bristol Myers Squibb (BMS) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to repotrectinib for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced, metastatic, or have no satisfactory alternative treatment or progressed following treatment.
Assuming you are a professional medical translator proficient in medical knowledge and English-Chinese translation, capable of accurately translating medical terminology, you are now required to use your expertise to accurately translate the above article into English. Ensure that medical terms are translated with precision, and the meaning is clear.
Content Source:百度百科